56015-98-6

Basic information

• Product Name: 4-iodobenzenesulfinic acid
• Synonyms: 4-iodobenzenesulfinic acid
• CAS NO: 56015-98-6
• Molecular Weight: 268.075
• Mol File: 56015-98-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-iodobenzenesulfinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-iodobenzenesulfinic acid(56015-98-6)
• EPA Substance Registry System: 4-iodobenzenesulfinic acid(56015-98-6)

Safety Data

• Hazardous Substances Data: 56015-98-6(Hazardous Substances Data)

Upstream product

• 19262-76-1 4-Iodo-benzenediazonium 
• 591-50-4 iodobenzene 
• 98-61-3 p-Iodobenzenesulfonyl chloride 

Downstream Products

• 1448709-49-6 3-((4-iodophenyl)thio)-1H-indole 
• 876617-07-1 4,4,5,5-tetramethyl-2-[4-(propane-1-sulfonyl)phenyl][1,3,2]dioxaborolane 
• 1384951-75-0 1-iodo-4-(propane-1-sulfonyl)benzene 
• 4533-14-6 S-(4-iodophenyl) 4-iodobenzenesulfonothioate 
• 13035-63-7 4-iodobenzenesulfonic acid 

Relevant articles and documents

Visible-Light-Induced Radical Cascade Cyclizations of 1,7-Enynes with Sulfinic Acids: Direct Access to Sulfonated Chromanes and Sulfonated Tetrahydroquinolines under Metal-Free Conditions

Visible-light-induced strategy to access sulfonated chromanes and sulfonated 1,2,3,4-tetrahydroquinolines via a radical cascade cyclization of 1-(arylethynyl)-2-(vinyloxy)benzenes and N-allyl-2-(arylethynyl)anilines with aromatic and aliphatic sulfinic acids has been developed. In the presence of TBHP (7.5 mol%) as an oxidant and Eosin Y (3.0 mol%) as a photocatalyst, the reactions undergo smoothly to afford the corresponding products in good yields at room temperature under metal-free conditions. This transformation features low loading of TBHP, mild reaction conditions, simple operation, broad functional-group tolerance, and good yields of products. (Figure presented.).

NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS

The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.